Tagged with Medicines for Africa

Africa Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties that wealthier countries rarely experience.   African countries face a difficult choice during outbreak situations. On one hand, they have…

Africa Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to building Africa’s healthcare autonomy.   In a turn of events that is both disappointing yet somehow not surprising, Moderna recently…

Africa Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the European Medicines Agency, and its progress thus far. Hwenda also examines how the AMA stands to impact Africa’s clinical trial…

Africa Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a swathe of “impact bottlenecks” unaddressed. Hwenda calls for a more holistic approach, moving beyond simply bringing medicines to African countries…